Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Risk Communication Research May Follow Critical Path To Avoid OMB

Executive Summary

FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts

You may also be interested in...

FDA Rule-Making Could Get Makeover Under Obama Administration

After GAO finds FDA one of the slower agencies in rulemaking, Rep. Towns asks for timeliness and transparency in White House input on federal regulations.

FDA And Health Reform: Commissioner Nominee Hamburg Takes Questions On Formularies, FOBs

Senate confirmation hearing focuses on access issues as much as it addresses regulation of medical products.

FDA Track Record In Risk Communication Raised As Key Sentinel Concern

FDA's ongoing challenges with effectively communicating the risks indicated by postmarket safety signals need to be resolved before the agency activates its Sentinel surveillance program, a number of participants said during a Dec. 16 FDA workshop

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts